Cagrilintide
Long-acting amylin analog
Cagrilintide (Long-acting amylin analog) is a metabolic & fat loss research compound. Lipidated amylin-receptor agonist — suppresses appetite and glucagon and slows gastric emptying (no insulin stimulation); pairs with semaglutide as CagriSema.
Cagrilintide quick facts
| Reported research dosing | 0.3mg-4.5mg |
| Route | Subq |
| Cycle length | As Long As Needed |
| Frequency | 1-2x Weekly (Split Dose) |
| Half-life | ~7–8 days (159–195 hrs) |
| Forms | Injectable |
| Evidence level | Human trials (CagriSema) |
Amylin is the missing puzzle piece — stacks beautifully with a GLP-1 for satiety.
How Cagrilintide works
Lipidated amylin-receptor agonist — suppresses appetite and glucagon and slows gastric emptying (no insulin stimulation); pairs with semaglutide as CagriSema.
Proposed benefits
Appetite and satiety support (amylin analog), often stacked with GLP-1s.
Where to get Cagrilintide
Buy Cagrilintide at AminoWell USA →Cagrilintide reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Cagrilintide
Graded by what exists behind each claim.
✅ Clinically validated
- Human phase 2 data as a standalone and, more importantly, as CagriSema — the cagrilintide/semaglutide combination — where REDEFINE-1 reported ~22.7% weight loss at 68 weeks. Phase 3 is complete for the combination; cagrilintide alone is not approved.
📊 Correlative data
- Little standalone real-world use; almost everyone running it is pairing it with a GLP-1, which is how it was developed and studied. Reported experience is of a smoother, less nauseating satiety than a GLP-1 alone.
🧪 Theoretical / extrapolated
- A long-acting amylin analog. Amylin is co-secreted with insulin and signals satiety through a different receptor system from GLP-1 — which is the entire mechanistic case for the combination: two independent satiety pathways rather than a bigger dose of one.
- Amylin agonism also slows gastric emptying, so the predicted interaction with a GLP-1 is additive on the GI side. That is what the titration schedule in the trials exists to manage.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Cagrilintide actually does
Cagrilintide is a long-acting analog of amylin, and the problem it was built to solve is that amylin is an amyloid. The hallmark of the native pancreatic hormone is its high propensity to form amyloid fibrils, which is what made it a hard drug design problem in the first place; the earlier analog in this class needed three injections a day because of its short half-life Kruse 2021. Cagrilintide is the lipidated, stabilized answer to both problems at once: a molecule that stays soluble and lasts a week.
The receptor question here is not GLP-1 versus amylin. It is amylin versus calcitonin, and the structures say cagrilintide barely distinguishes them. An amylin receptor is the calcitonin receptor (CTR) in complex with a receptor-activity-modifying protein: CTR+RAMP1 is AMY1, CTR+RAMP2 is AMY2, CTR+RAMP3 is AMY3. Cryo-EM structures have been solved of cagrilintide bound to AMY1R, AMY2R, AMY3R and CTR in the Gs-coupled active state, and the reported binding mode is amylin-like at all of them Cao 2025. A parallel structural study describes a shared ‘bypass’ binding mode that explicitly enables non-specific binding and activation across different receptors Gu 2025.
That non-selectivity is the design, not a defect — and it has a name. Molecules of this shape are dual amylin and calcitonin receptor agonists, and the argument for hitting both is that the calcitonin arm sustains the effect where a pure amylin agonist desensitizes. It is an argument, and the mouse work below is the closest anyone has come to testing it.
Which receptor actually produces the weight loss, answered by knockout. In RAMP1/RAMP3 knockout mice, cagrilintide lowered body weight (−3.4 ± 0.51 g, P < 0.005, n = 8 per group) and cut day-one food intake from 2.7 ± 0.2 g on vehicle to 1.2 ± 0.1 g, P < 0.0001. Salmon calcitonin, which prefers the bare calcitonin receptor, increased body weight instead (+0.60 ± 0.38 g, P < 0.01), and the authors attribute cagrilintide’s effect to brain amylin receptors 1 and 3 Carvas 2025.
Read those two paragraphs together and the ratio question has a functional answer even though no potency table has been published: cagrilintide binds CTR and the AMY receptors alike, and only the RAMP-containing ones produce weight loss. Everything it does at bare CTR is, for the purpose people buy it for, off-target — and bare CTR is where calcitonin’s effects on bone and serum calcium live. Nobody in this market states that, and it is the single most useful sentence on this page.
Cell, rodent, human — and where it stops
Step one, chemistry. Amylin’s fibril problem, and a lipidated analog engineered around it for once-weekly dosing Kruse 2021.
Step two, structures. Cryo-EM at AMY1R, AMY2R, AMY3R and CTR Cao 2025, and an independent structural account of the ‘bypass’ mode that makes the cross-receptor activation possible Gu 2025.
Step three, mice, with a genetic control. RAMP1/RAMP3 knockouts, cagrilintide against salmon calcitonin against vehicle, 8 animals per group, weight and food intake as read-outs Carvas 2025.
Step four, humans — and here is the problem with this compound’s entire clinical record. The phase 3 program studies cagrilintide as half of a combination. In REDEFINE 1 (NCT05567796), 3,417 participants were randomized over 68 weeks: 2,108 to cagrilintide–semaglutide, 302 to semaglutide alone, 302 to cagrilintide alone, and 705 to placebo. The primary endpoint, estimated mean percent change in body weight at week 68, was −20.4% on the combination against −3.0% on placebo, an estimated difference of −17.3 percentage points, and it was met. Gastrointestinal adverse events affected 79.6% of the combination group against 39.9% on placebo Garvey 2025.
Now the sentence that matters for this page: the abstract does not report what the 302 people on cagrilintide alone weighed at week 68. Three hundred and two participants took this exact compound as monotherapy for sixty-eight weeks in a phase 3 trial, and the headline number that circulates for it — the one on every vendor page — is the combination’s −20.4% Garvey 2025.
Step five, the second phase 3, where the same thing happens again. REIMAGINE 2 (NCT06065540) randomized 2,713 people with type 2 diabetes over 68 weeks across six arms: cagrilintide–semaglutide 2.4 mg each (n = 603), semaglutide 2.4 mg (n = 605), cagrilintide 2.4 mg alone (n = 152), cagrilintide–semaglutide 1.0 mg each (n = 595), semaglutide 1.0 mg (n = 609) and placebo (n = 149). Mean baseline HbA1c 8.2% (SD 0.9). The primary endpoint was HbA1c change and it was met: −1.91 percentage points on the combination against −1.75 on semaglutide 2.4 mg. Adverse events occurred in 86.9% (combination), 81.2% (semaglutide 2.4 mg), 82.2% (cagrilintide 2.4 mg alone) and 70.5% (placebo) Buse 2026.
Step six, two clean human pharmacology studies that do belong to cagrilintide alone. A thorough QT study (NCT05804162) in 105 participants — 53 on cagrilintide, 52 on placebo — measured time-matched change from baseline in Fridericia-corrected QT at 12, 24, 48 and 72 hours after the last 4.5 mg dose; the upper limits of the two-sided 90% confidence intervals stayed below 10 ms at every time point Gabe 2024. And two impairment studies — 33 participants across normal, mild, moderate and severe renal impairment, and 32 participants across the same grades of hepatic impairment — found exposure ratios of 0.99 to 1.23 with no clinically relevant differences Nielsen 2026.
The obstacles, one at a time. (1) Every published phase 3 efficacy number for this molecule is a combination number, while 454 people across two trials took it alone and their results are not in the abstracts Garvey 2025 Buse 2026. (2) No potency ratio between the AMY receptors and bare CTR has been published, so the structural non-selectivity Cao 2025 Gu 2025 cannot be quantified. (3) The knockout experiment that assigns the effect to AMY1 and AMY3 was done in mice Carvas 2025. (4) No calcium, bone-turnover or bone-density data from any human trial, despite structurally demonstrated calcitonin receptor activation. (5) The card’s dose range, 0.3–4.5 mg, comes from the dose-finding era; the phase 3 dose is 2.4 mg Buse 2026 and the QT study dosed 4.5 mg Gabe 2024.
Cagrilintide pharmacokinetics — how much of it actually gets in
The card says ‘~7–8 days (159–195 hrs)’. That is a precise-looking figure, and none of the eight papers behind this page states it. The two human pharmacokinetic studies that exist report exposure ratios rather than a half-life Nielsen 2026. So treat the card’s range as an inference from once-weekly dosing rather than as a measurement, and note that the inference is a reasonable one: four to five half-lives is what a weekly peptide needs to reach steady state, which places it in the 5-to-8-day neighborhood.
What holds it in the body. Lipidation Kruse 2021. A fatty acyl chain binds albumin reversibly, and albumin-bound peptide is too large to be filtered at the glomerulus and is shielded from circulating peptidases; the free fraction is replenished continuously from that reservoir. This is the same principle as every weekly agent in this cohort.
What clears it — and there is a real measurement here that is worth more than the missing half-life. Exposure was essentially unchanged across mild, moderate and severe renal impairment and across mild, moderate and severe hepatic impairment, with AUC ratios of 0.99 to 1.23 Nielsen 2026. A drug that is indifferent to both organs is not being cleared principally by either. What is left is proteolysis of the free fraction in plasma and tissue, which is exactly what you would predict for an albumin-bound peptide and is rarely demonstrated this cleanly.
What degrades it, at the molecular level. Peptide bonds, cut by plasma and tissue peptidases. There is no cytochrome involvement, so there is no metabolic drug interaction; the interaction that matters is mechanical, because amylin agonism slows gastric emptying and therefore changes the absorption rate of anything swallowed with it.
The formulation risk that is specific to this molecule. The parent hormone’s defining chemical behavior is fibril formation Kruse 2021. Aggregation propensity is a property that engineering suppresses rather than abolishes, and it is concentration-, temperature- and pH-dependent. For a reconstituted research-market vial that means the storage conditions are not boilerplate: a cloudy or stringy solution in this particular compound is the failure mode its whole design was built to avoid.
The oral barrier and the route. Absolute, and subcutaneous. Every dose in every study cited here was injected weekly.
What would have to be true, and how you would know it was not
Four predictions. The second is the one this compound’s own structural biology demands and no trial has reported.
1. HbA1c and fasting insulin should fall, and less than people expect. In the diabetes phase 3, the combination beat semaglutide alone by 0.16 percentage points of HbA1c — statistically significant, clinically modest Buse 2026. Draw HbA1c and fasting insulin at baseline, 12 and 24 weeks. Amylin’s glycemic contribution is mostly post-prandial and mostly through gastric emptying, so a large HbA1c move from cagrilintide alone would be a surprise rather than a confirmation.
2. Serum calcium is the missing measurement, and it is on a panel you already order. Cagrilintide activates the bare calcitonin receptor in the Gs-coupled active state Cao 2025 Gu 2025, and calcitonin’s defining action is lowering serum calcium by suppressing osteoclasts. A CMP contains calcium. Draw it at baseline and at 12 and 24 weeks. The prediction is a small fall or none; a reproducible fall would be the first human evidence that the calcitonin arm is engaged at ordinary doses, and it would move the bone question from theoretical to real.
3. Resting heart rate should NOT rise, and that is the prediction that distinguishes this drug from everything else on this shelf. Incretin agonists raise resting pulse as a class effect. Amylin agonism has no such mechanism, and the thorough QT study found the upper bound of the QTcF change below 10 ms at 12, 24, 48 and 72 hours after a 4.5 mg dose Gabe 2024. Take a seated morning pulse before caffeine for a week before starting and weekly after. A pulse that climbs 8–10 beats on what is sold as cagrilintide is evidence of an incretin in the vial, and for a research-market purchase that is the cheapest identity check available.
4. And the prediction that cuts against the compound. The −20.4% number attached to this molecule everywhere belongs to cagrilintide plus semaglutide, in 2,108 people Garvey 2025. Anyone running cagrilintide alone should expect a substantially smaller result — and should record their own weekly weight against it, because the honest comparator does not exist in the published abstracts. If a solo user matches 20% over 68 weeks, either the monotherapy arm was far better than anyone has said, or something else is in the vial.
What nobody has tested yet
Five experiments, and the first one has already been done — the result simply has not been published.
1. The monotherapy result exists and nobody can read it. 302 people took cagrilintide alone for 68 weeks in REDEFINE 1 and 152 took it alone for 68 weeks in REIMAGINE 2 Garvey 2025 Buse 2026. That is 454 people of monotherapy data at phase 3 quality, and neither abstract states their weight change. Publishing one number for each arm would tell every buyer of this compound what it actually does on its own.
2. Nobody has published the AMY-to-CTR potency ratio. Four cryo-EM structures have been solved Cao 2025 and a second group has described the binding mode independently Gu 2025, and there is still no table of EC50 values at AMY1, AMY2, AMY3 and bare CTR. The assay is routine; the number decides how much calcitonin pharmacology a user is buying with their amylin.
3. Nobody has measured bone. Chronic calcitonin receptor agonism suppresses osteoclasts, and the closest published comparison in this Vault is a different non-erythropoietic peptide that raised murine bone mineral density by roughly 5% in a month Awida 2021. Cagrilintide has been given to thousands of people for 68 weeks Garvey 2025 and no bone-turnover marker, no calcium and no densitometry appears in the abstract record.
4. Nobody has tested whether amylin resets the defended weight after the drug stops. The theoretical case for the amylin axis is that it lowers the body’s defended set point rather than only opposing intake. The experiment is a randomized withdrawal: stop the drug at week 68 and follow weight for a year against a GLP-1 arm stopped the same week. Nobody has run it for this molecule, and it is the difference between a treatment and a cure.
5. Nobody has compared it head-to-head with the older amylin analog at matched receptor occupancy. The earlier drug needed three injections a day Kruse 2021; this one needs one a week. Whether a flat weekly exposure produces more, less or the same effect than three daily peaks — at the same total receptor engagement — has never been measured, and it is the whole question of whether continuous amylin signaling desensitizes.
Cagrilintide — its own safety story, not its class's
The class block on this page is written for GLP-1 receptor agonists. This compound is not one, and five things below are its own.
1. It has a negative thorough QT study, which almost nothing else in this catalog does. 105 participants, 53 on drug, QTcF measured at four time points after a 4.5 mg dose, all upper confidence bounds under 10 ms Gabe 2024. That is a real, regulator-grade cardiac safety result for the molecule alone, and it is stronger evidence than most compounds here will ever have.
2. Renal and hepatic impairment do not change exposure. AUC ratios 0.99 to 1.23 across mild, moderate and severe impairment of each organ, in 33 and 32 participants respectively Nielsen 2026. This is unusual and it is genuinely useful: it means the two organ systems that normally force dose adjustment do not for this drug.
3. Its own gastrointestinal burden is smaller than the combination’s, and the numbers separate cleanly. On the combination, gastrointestinal adverse events hit 79.6% against 39.9% on placebo Garvey 2025. In the diabetes trial, total adverse events were 82.2% on cagrilintide alone against 70.5% on placebo — about twelve percentage points — while the combination sat at 86.9% Buse 2026. Most of the misery in CagriSema belongs to the GLP-1 half.
4. The calcitonin receptor is this molecule’s unmeasured risk. It activates bare CTR structurally Cao 2025 Gu 2025 and no human trial has reported serum calcium or bone markers. This is not a warning that something bad has happened; it is a statement that the obvious question raised by the drug’s own structural biology has not been asked in a person.
5. The aggregation question, which belongs in a safety section rather than a storage note. Native amylin is amyloidogenic Kruse 2021, and injecting an aggregated peptide is a different immunological proposition from injecting a soluble one. The engineered molecule is stabilized, but nothing published describes how a research-market vial behaves after reconstitution, warm shipping or repeated withdrawal — and this is the one compound in this cohort where that specific failure mode is written into the parent hormone’s chemistry.
Sources read for this page
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry 2021 · PMID 34288673
- Cao J, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications 2025 · PMID 40204768
- Gu YM, et al. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica 2025 · PMID 40847076
- Carvas AO, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine 2025 · PMID 40609154
- Nielsen MJF, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clinical Pharmacokinetics 2026 · PMID 42228334
- Gabe MBN, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, Obesity and Metabolism 2024 · PMID 39279639
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2025 · PMID 40544433
- Buse JB, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The Lancet Diabetes & Endocrinology 2026 · PMID 42251859
- Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences 2021 · PMID 35008482
Cagrilintide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Any time — but the same day each week
With a half-life measured in days you are dosing into a standing level, so the hour is irrelevant and the consistency is not. Pick a day and hold it; drifting the interval is what produces the peaks and troughs people mistake for the drug not working.
Food makes no meaningful difference at this half-life.
From half-life and route, not a dosing trial.
Cagrilintide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Cagrilintide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Cagrilintide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Baseline — an amylin analog, usually paired with a GLP-1 |
| Fasting Insulin | The metabolic readout |
| Comprehensive Metabolic Panel (CMP) | Glucose, liver and kidney |
| Lipase | Monitored alongside whatever incretin it's paired with |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cagrilintide — frequently asked questions
What is Cagrilintide?
Cagrilintide (Long-acting amylin analog) is a metabolic & fat loss research compound. Lipidated amylin-receptor agonist — suppresses appetite and glucagon and slows gastric emptying (no insulin stimulation); pairs with semaglutide as CagriSema.
What dosing does the research reference for Cagrilintide?
In the research literature, Cagrilintide is referenced in the 0.3mg-4.5mg range, 1-2x Weekly (Split Dose). It is supplied as a lyophilized powder and reconstituted with acetic acid/bac water; the calculator above converts a research amount into syringe units. For research use only — not a recommendation for human use.
What is the half-life of Cagrilintide?
Cagrilintide has an approximate half-life of ~7–8 days (159–195 hrs), which is part of what determines how often it's dosed.
What's the evidence behind Cagrilintide?
Current evidence level: Human trials (CagriSema). Cagrilintide is offered for research purposes only and is not an approved medicine.
Cagrilintide inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Cagrilintide is used for
Cagrilintide appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
Cagrilintide is the appetite arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.